Sensorion’s Oral SENS-401 prevented cisplatin-induced hearing loss

Preclinical data

Sensorion SENS_401

In regulatory news reported by Business Insider, Sensorion, a biotech company developing novel treatments for inner ear diseases, recently published findings showing that orally administered SENS-401 significantly prevented cisplatin-induced hearing loss in preclinical models.

Cisplatin is a widely used chemotherapy treatment that induces severe hearing loss in 50–60% of treated patients. The preclinical study involved a series of in vitro and in vivo investigations to evaluate the protective potential and pharmacokinetics of SENS-401 in this indication.

Study rats were randomly administered a daily oral dose of either SENS-401 or placebo, immediately followed by a 30-minute intravenous infusion of cisplatin. Daily oral SENS-401 treatment was continued for a total of 14 consecutive days. The study evaluated three doses of SENS-401: 6.6, 13.2, and 26.4 mg/kg/day.

The results were published in September in the Journal of Otology & Neurotology and showed that all doses were associated with significant activity (improvement of more than 50%) in the prevention of cisplatin-induced hearing loss, compared to placebo. All doses of oral SENS-401 significantly reduced the loss of outer hair cells by up to 10 fold. Sensorion is seeking orphan drug designation for this compound from the US Food and Drug Administration (FDA).

Source: Business Insider